5th to 6th of October IBSA will be present as official partner at CPhI Festival of Pharma.
During this 2020 virtual edition, IBSA will be presenting its offer of innovative products, related to all the main therapeutic areas of expertise: Fertility, Endocrinology, Osteoarticular, Urology, ENT, Ophtalmic, Consumer Heatlh and much more.
A further focus will be on the technologies for which IBSA’s expertise is recognized internationally: ODF technology (orodispersible film), softgel (PEARLtec technology) and injectables, as well as many others.
In fact, the company’s R&D activity employs advanced technology to study innovative ways of administering medicines and supplements, such as:
- the exclusive Softgel technology allows either an oily solution or a suspension to be incorporated into a tasteless and odourless gelatine capsule. Easy and practical to swallow, it assures the assumption of active ingredients or supplements improving patient compliance.
- the Orodispersible Film, available in a variety of polymers, represents a brand new concept in the oral administration of medicines and supplements, overcoming the need for either water or swallowing. It comes in the form of a thin strip which is placed on the upper part of the tongue where it dissolves in seconds releasing its active ingredients.
- the injectable formulations, in both aseptic conditions and with terminal sterilisation, are produced under the form of traditional ampoules from 1 to 5 ml and pre-filled syringes from 1 to 3 ml filled with high and low viscosity products
Founded in Lugano in 1945, thanks to a consolidated expansion strategy, IBSA is present with its products in 5 continents and in over 80 countries, including China and the United States, and has a strategic commercial partnership with Laboratoires Genevrier in France. Overall, the Group employs 2,000 people, spread among the various offices and production sites of its 13 branches in Europe, China and the United States, while 116 people work in the 14 Research and Development laboratories.
Science, innovation and technology have always distinguished the history of IBSA and, together with important investment in research and development, they have allowed the company to develop a wide portfolio of unique and innovative products (medicines, supplements and medical devices).
Today, thanks to its consolidated experience, its industrial capacity and its proprietary technologies, IBSA is the ideal partner for innovation and development processes that can provide a complete service, from product concept to large-scale production for European and non-EU markets.
Find out more on our website: https://www.ibsagroup.com and www.ibsa.it
